NCT04355676View on ClinicalTrials.gov

Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2020

Primary Completion Date

August 30, 2020

Study Completion Date

August 30, 2020

Conditions
Coronavirus Infection
Interventions
DRUG

Selinexor

20 mg selinexor oral tablet.

Sponsors
All Listed Sponsors
lead

Karyopharm Therapeutics Inc

INDUSTRY